Enliven Therapeutics
ELVN | NASDAQ
$47.62
-$1.18 (-2.42%)
At close: Nov 16, 2026, 4:00 PM ET
$47.62
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Enliven Therapeutics Company Profile
Company profile explainedCompany Profile
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Key Executives
| Name | Position |
|---|---|
| Richard A. Fair | CEO, President & Director |
| Anish Patel | Co-Founder & Chief Operating Officer |
| Benjamin Hohl | Chief Financial Officer & Head of Corporate Development |
| Galya D. Blachman | Chief Legal Officer & Head of Business Development |
| Damiette Smit | Vice President of Clinical Development |
| Helen Louise Collins | Chief Medical Officer |
| Joseph Lyssikatos | Co-Founder & Research Fellow |
| Samuel S. Kintz | Co-Founder & Head of Pipeline |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 21, 2026 | 4 | Filing |
| Oct 21, 2026 | 4 | Filing |
| Oct 16, 2026 | 4 | Filing |
| Oct 16, 2026 | 3 | Filing |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 4 | Filing |
| Sep 21, 2026 | 4 | Filing |
| Sep 21, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
Enliven Therapeutics
| Country | United States |
| IPO Date | Mar 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 67 |
| CEO | Richard A. Fair |
Contact Details
6200 Lookout Road Boulder,
Colorado 80301 United States
Stock Details
| Ticker Symbol | ELVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001672619 |
| CUSIP Number | 29337E102 |
| ISIN Number | US29337E1029 |
| SIC Code | 2834 |
Recent News
- 11 days ago / prnewswire.comEnliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
- 1 month ago / prnewswire.comEnliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
- 2 months ago / benzinga.comThis Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
- 2 months ago / seekingalpha.comEnliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / prnewswire.comEnliven Therapeutics to Present at Upcoming Investor Conferences
- 2 months ago / seekingalpha.comEnliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing
- 3 months ago / benzinga.comEnliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
- 3 months ago / prnewswire.comEnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
- 5 months ago / prnewswire.comEnliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- 5 months ago / gurufocus.comEnliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Add to Watchlist
Select watchlists to add or remove ELVN